vc-mmad

Vc-MMAD, a drug-linker conjugate for Antibody-Drug Conjugates (ADCs), combines the ADC linker Val-Cit (Valine-Citrulline) with the potent tubulin inhibitor MMAD. This compound leverages the targeting capability of ADCs to deliver the cytotoxic agent MMAD specifically to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects.

DBCO-PEG4-VC-PAB-MMAD is a click-reactive Drug-linker that contains a DBCO group and can undergo a strain-promoted acetylene-nitride cycloaddition reaction (SPAAC) with molecules containing an Azide group. MMAD is an effective microtubule (tubulin) inhibitor. DBCO-PEG4-VC-PAB-MMAF, DBCO-PEG4-VC-PAB-MMAD can be used in the synthesis of antibody-drug conjugates (ADC).

OSu-Glu-VC-PAB-MMAD is an agent-linker conjugate used in antibody-drug conjugates (ADCs) with potent antitumor activity. It features MMAD, a powerful tubulin inhibitor, linked via the cleavable ADC linker OSu-Glu-VC-PAB, enabling targeted cancer therapy.

MC-VC-PAB-MMAD is a conjugate for antibody-drug conjugates (ADCs) that exhibits potent antitumor activity by employing MMAD, a powerful tubulin inhibitor, connected through the cleavable ADC linker MC-VC-PAB [1].